[Results of an anti-hepatitis-B vaccination in a population at risk].
135 subjects, belonging to the sanitary staff and the dialyzed patients (high-risk classes) of the Ospedale Maggiore in Crema, have been vaccinated against hepatitis B with Hevac B vaccine produced by Pasteur firm. We have followed the vaccination protocol advised by the producer firm: subcutaneous administration in the deltoid region of three doses at one month intervals. One year after the third dose a further one was administered. Each dose of vaccine contains 5 micrograms of purified and inactivated HBsAg. We have investigated the presence of HBsAb, as protection standard, using EIA Abbott. 30 days after the first dose, HBsAb was present in 7.3% of the subjects; this percentage increased until 26.5% after the second dose and until 77.7% after the third one. One month after the fourth dose 95.6% appeared serologically protected against HBV. Secondary reactions to vaccine have been negligible.